Engineered Spider Venom Peptide Pn3a Variant Is 20x More Potent at Pain Channel NaV1.7
A single amino acid change (D8N) in the spider venom peptide Pn3a increased its potency at the pain channel NaV1.7 by 20-fold while maintaining selectivity and reducing pain in mice at lower doses.
Quick Facts
What This Study Found
The Pn3a[D8N] mutation increased NaV1.7 inhibition potency 20-fold while maintaining >100-fold selectivity over NaV1.4, NaV1.5, and NaV1.6, with confirmed analgesic activity at lower doses in vivo.
Key Numbers
D8N: 20-fold potency; >100-fold selectivity over NaV1.4/1.5/1.6; 3-fold lower dose in vivo; K22/K24 essential; Y4/Y27/W30 >250-fold loss
How They Did This
Rational peptide engineering with 17 Pn3a analogues tested via patch-clamp electrophysiology, molecular modeling of channel interactions, and in-vivo postsurgical pain model in mice.
Why This Research Matters
NaV1.7 is a validated pain target with strong human genetic evidence. Engineering more potent and selective peptide inhibitors brings us closer to non-opioid pain therapeutics.
The Bigger Picture
This work advances the development of peptide-based pain drugs that could offer alternatives to opioids, using venom-derived scaffolds refined through rational engineering.
What This Study Doesn't Tell Us
Mouse pain model — human translation needed; peptide delivery challenges for clinical use; long-term safety not assessed; D8N improvement is still preclinical.
Questions This Raises
- ?Can Pn3a[D8N] be formulated for practical clinical delivery?
- ?Would further engineering yield even more potent NaV1.7-selective analgesics?
- ?How does Pn3a compare to small-molecule NaV1.7 inhibitors in development?
Trust & Context
- Key Stat:
- 20-fold potency increase Pn3a[D8N] single mutation improved NaV1.7 inhibition while maintaining >100-fold channel selectivity
- Evidence Grade:
- Strong structure-activity data with 17 analogues, validated by in-vivo pain model showing functional improvement — rigorous preclinical evidence.
- Study Age:
- Published in 2020; NaV1.7-targeted peptide analgesics remain an active area of non-opioid pain drug development.
- Original Title:
- Mapping the Molecular Surface of the Analgesic NaV1.7-Selective Peptide Pn3a Reveals Residues Essential for Membrane and Channel Interactions.
- Published In:
- ACS pharmacology & translational science, 3(3), 535-546 (2020)
- Authors:
- Mueller, Alexander, Dekan, Zoltan, Kaas, Quentin(3), Agwa, Akello J, Starobova, Hana, Alewood, Paul F, Schroeder, Christina I, Mobli, Mehdi, Deuis, Jennifer R, Vetter, Irina
- Database ID:
- RPEP-05015
Evidence Hierarchy
Frequently Asked Questions
Can spider venom treat pain?
Spider venom peptides like Pn3a selectively block NaV1.7, a sodium channel genetically linked to pain. Engineered variants are being developed as potential non-opioid painkillers.
What is NaV1.7 and why target it?
NaV1.7 is a sodium channel in pain-sensing nerves. People born without functional NaV1.7 cannot feel pain, making it a prime target for non-addictive analgesic drugs.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05015APA
Mueller, Alexander; Dekan, Zoltan; Kaas, Quentin; Agwa, Akello J; Starobova, Hana; Alewood, Paul F; Schroeder, Christina I; Mobli, Mehdi; Deuis, Jennifer R; Vetter, Irina. (2020). Mapping the Molecular Surface of the Analgesic NaV1.7-Selective Peptide Pn3a Reveals Residues Essential for Membrane and Channel Interactions.. ACS pharmacology & translational science, 3(3), 535-546. https://doi.org/10.1021/acsptsci.0c00002
MLA
Mueller, Alexander, et al. "Mapping the Molecular Surface of the Analgesic NaV1.7-Selective Peptide Pn3a Reveals Residues Essential for Membrane and Channel Interactions.." ACS pharmacology & translational science, 2020. https://doi.org/10.1021/acsptsci.0c00002
RethinkPeptides
RethinkPeptides Research Database. "Mapping the Molecular Surface of the Analgesic NaV1.7-Select..." RPEP-05015. Retrieved from https://rethinkpeptides.com/research/mueller-2020-mapping-the-molecular-surface
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.